Urology
Volume 75, Issue 2 , Pages 478-481 , February 2010

Impact of Disease Burden on Cryoablation Prostate-specific Antigen Outcomes

  • David A. Levy

      Affiliations

    • Department of Regional Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    • Corresponding Author InformationReprint requests: David A. Levy, M.D., Department of Urology and Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, 18200 Lorain Ave, Cleveland, OH 44111
    • ,
  • Jianbo Li

      Affiliations

    • Department of Quantitative Health Sciences, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Stephen Jones

      Affiliations

    • Department of Regional Urology, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, Ohio

Received 23 June 2009 ,Accepted 25 September 2009.

References 

  1. Karakiewicz PI, Bhojani N, Capitanio U, et al. External validation of the updated Partin tables in a cohort of North American men. J Urol. 2008;180:898–902
  2. Bhojani N, Salomon L, Capitanio U, et al. External validation of the updated Partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys. 2009;73:347–352
  3. D'Amico AV, Moul J, Carroll PR, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. J Clin Oncol. 2003;21:2163–2172
  4. Molitierno J, Evans A, Mohler JL, et al. Characterization of biochemical recurrence after radical prostatectomy. Urol Int. 2006;77:130–134
  5. Sengupta S, Christensen CM, Zinke H, et al. Detectable prostate-specific antigen 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol. 2006;176:559–563
  6. Lin DD, Schultz D, Renshaw AA, et al. Predictors of short postoperative prostate specific antigen doubling time for patients diagnosed during the PSA era. Urology. 2005;65:528–532
  7. Teeter AE, Banez LL, Presti JC, et al. What are factors associated with short prostate specific antigen doubling time after radical prostatectomy? (A report from the SEARCH database group). J Urol. 2008;180:1980–1984
  8. Naselli A, Introini C, Andreatta R, et al. Prognostic factors of persistently detectable PSA after radical prostatectomy. Int J Urol. 2009;16:82–86
  9. Shikanov SA, Thong A, Gofrit ON, et al. Robotic laparoscopic radical prostatectomy for biopsy Gleason 8 to 10: prediction of favorable pathologic outcome with preoperative parameters. J Endourol. 2008;22:1477–1481
  10. D'Amico AV, Schultz D, Silver B, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:679–684
  11. Freedland SJ, Aronson WJ, Terris MK, et al. The SEARCH Database Study Group Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol. 2003;169:2136–2141
  12. Harnden P, Shelly MD, Naylor B, et al. Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? (A systematic review). Eur Urol. 2008;54:728–739
  13. Sebo TJ, Bock BJ, Cheville JC, et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000;163:179–180
  14. Spalding AC, Daignault S, Sandler HM, et al. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. Urology. 2007;69:936–940
  15. Levy DA, Pisters LL, Jones JS. Primary cryoablation Nadir prostate specific antigen and biochemical failure. J Urol. 2009;182:931–937
  16. D'Amico AV, Moul J, Carroll PR, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate specific antigen era. J Clin Oncol. 2003;21:2163–2172

PII: S0090-4295(09)02679-X

doi: 10.1016/j.urology.2009.09.054

Urology
Volume 75, Issue 2 , Pages 478-481 , February 2010

Article Tools